肿瘤细胞治疗研究
英文原题：Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
T 细胞急性淋巴细胞白血病/淋巴瘤（T-ALL/LBL）是一种起源于祖 T 细胞的侵袭性恶性肿瘤。
T细胞急性淋巴细胞白血病/淋巴瘤（T-ALL/LBL）是一种侵袭性祖细胞T细胞恶性肿瘤。过去几十年，T-ALL/LBL患者生存率显著提高，但复发/难治性T-ALL/LBL（R/R T-ALL/LBL）的治疗仍极具挑战。无法耐受强化化疗的患者预后仍然较差，因此需要创新方法进一步改善其生存。随着新一代测序在T-ALL/LBL中的广泛应用，研究者发现了一系列新的治疗靶点，如NOTCH1抑制剂、JAK-STAT抑制剂和酪氨酸激酶抑制剂，并推动相关分子靶向治疗进入临床前研究和临床试验。此外，CD7 CAR-T 和CD5 CAR-T 免疫疗法在R/R T-ALL/LBL中显示出较高缓解率。本文综述T-ALL/LBL靶向治疗和免疫治疗的进展，并展望进一步应用这些疗法的未来方向与挑战。
T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of progenitor T cells. Despite significant improvements in survival of T-ALL/LBL over the past decades, treatment of relapsed and refractory T-ALL (R/R T-ALL/LBL) remains extremely challenging. The prognosis of R/R T-ALL/LBL patients who are intolerant to intensive chemotherapy remains poor. Therefore, innovative approaches are needed to further improve the survival of R/R T-ALL/LBL patients. With the widespread use of next-generation sequencing in T-ALL/LBL, a range of new therapeutic targets such as NOTCH1 inhibitors, JAK-STAT inhibitors, and tyrosine kinase inhibitors have been identified. These findings led to pre-clinical studies and clinical trials of molecular targeted therapy in T-ALL/LBL. Furthermore, immunotherapies such as CD7 CAR T cell therapy and CD5 CAR T cell therapy have shown profound response rate in R/R T-ALL/LBL. Here, we review the progress of targeted therapies and immunotherapies for T-ALL/LBL, and look at the future directions and challenges for the further use of these therapies in T-ALL/LBL.
MEMBER ACCOUNT
登录成功会直接打开下一页。
